{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T06:40:33Z","timestamp":1785652833155,"version":"3.56.0"},"reference-count":210,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40744-025-00779-1","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:18:17Z","timestamp":1752139097000},"page":"741-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Saudi Clinical Practice Guidelines for Management of Axial Spondyloarthritis Disease"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-0831","authenticated-orcid":false,"given":"Hanan","family":"Al Rayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4650-3338","authenticated-orcid":false,"given":"Nayef","family":"Al Ghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-6193","authenticated-orcid":false,"given":"Hajer Y.","family":"Almudaiheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5617-5008","authenticated-orcid":false,"given":"Mohamed","family":"Bedaiwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6362-8549","authenticated-orcid":false,"given":"Mansour","family":"Alazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1863-4509","authenticated-orcid":false,"given":"Eman","family":"Alqurtas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2266-7394","authenticated-orcid":false,"given":"Haifa F.","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-6248","authenticated-orcid":false,"given":"Waleed","family":"Hafiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-8983","authenticated-orcid":false,"given":"Sultana","family":"Abdulaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-4332","authenticated-orcid":false,"given":"Khalidah A.","family":"Alenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-4870","authenticated-orcid":false,"given":"Bedor A.","family":"Al-Omari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-6938","authenticated-orcid":false,"given":"Ibrahim","family":"Alhomood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-7292","authenticated-orcid":false,"given":"Jameel T.","family":"Abualenain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-9086","authenticated-orcid":false,"given":"Ahmed H.","family":"Al-Jedai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"779_CR1","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127\u201337.","journal-title":"Lancet"},{"key":"779_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2040622317743486","volume":"9","author":"S Dubash","year":"2018","unstructured":"Dubash S, McGonagle D, Marzo-Ortega H. New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. Ther Adv Chronic Dis. 2018;9:77\u201387.","journal-title":"Ther Adv Chronic Dis"},{"key":"779_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001136","volume":"6","author":"P Carron","year":"2020","unstructured":"Carron P, De Craemer A-S, Van den Bosch F. Peripheral spondyloarthritis: a neglected entity\u2014state of the art. RMD Open. 2020;6:e001136.","journal-title":"RMD Open"},{"key":"779_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73\u201384.","journal-title":"Lancet"},{"key":"779_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/1824794","volume":"2017","author":"AN Malaviya","year":"2017","unstructured":"Malaviya AN, Rawat R, Agrawal N, Patil NS. The nonradiographic axial spondyloarthritis, the radiographic axial spondyloarthritis, and ankylosing spondylitis: the tangled skein of rheumatology. Int J Rheumatol. 2017;2017:1\u20139.","journal-title":"Int J Rheumatol"},{"key":"779_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard-2023-225185","volume":"83","author":"D van der Heijde","year":"2024","unstructured":"van der Heijde D, Molto A, Ramiro S, et al. Goodbye to the term \u2018ankylosing spondylitis\u2019, hello \u2018axial spondyloarthritis\u2019: time to embrace the ASAS-defined nomenclature. Ann Rheum Dis. 2024;83:547\u20139.","journal-title":"Ann Rheum Dis"},{"key":"779_CR7","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.20990","volume":"52","author":"M Rudwaleit","year":"2005","unstructured":"Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 2005;52:1000\u20138.","journal-title":"Arthritis Rheum"},{"key":"779_CR8","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:ii1-44.","journal-title":"Ann Rheum Dis"},{"key":"779_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","volume":"78","author":"A Boel","year":"2019","unstructured":"Boel A, Molto A, van der Heijde D, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis. 2019;78:1545\u20139.","journal-title":"Ann Rheum Dis"},{"key":"779_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777\u201383.","journal-title":"Ann Rheum Dis"},{"key":"779_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-017-1333-x","volume":"19","author":"L van Hoeven","year":"2017","unstructured":"van Hoeven L, Boonen AERCH, Hazes JMW, Weel AEAM. Work outcome in yet undiagnosed patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis; results of a cross-sectional study among patients with chronic low back pain. Arthritis Res Ther. 2017;19:143.","journal-title":"Arthritis Res Ther"},{"key":"779_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.mpmed.2018.01.005","volume":"46","author":"C Raine","year":"2018","unstructured":"Raine C, Keat A. Axial spondyloarthritis. Medicine (Baltimore). 2018;46:231\u20136.","journal-title":"Medicine (Baltimore)"},{"key":"779_CR13","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/annrheumdis-2013-204953","volume":"74","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, van Tubergen A, Stolwijk C, van der Heijde D, Royston P, Landew\u00e9 R. Reference intervals of spinal mobility measures in normal individuals: the mobility study. Ann Rheum Dis. 2015;74:1218\u201324.","journal-title":"Ann Rheum Dis"},{"key":"779_CR14","doi-asserted-by":"crossref","unstructured":"Michelena X, Zhao SS, Marco-Pascual C, et al. Diagnostic delay is associated with uveitis and inflammatory bowel disease in AS: a study of extra-musculoskeletal manifestations in SpA. Rheumatology (Oxford). 2024;63(2):430\u201335.","DOI":"10.1093\/rheumatology\/kead225"},{"key":"779_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12891-015-0853-2","volume":"16","author":"L Hamilton","year":"2015","unstructured":"Hamilton L, Macgregor A, Toms A, Warmington V, Pinch E, Gaffney K. The prevalence of axial spondyloarthritis in the UK: a cross-sectional cohort study. BMC Musculoskelet Disord. 2015;16:392.","journal-title":"BMC Musculoskelet Disord"},{"key":"779_CR16","doi-asserted-by":"publisher","first-page":"1759720X2199697","DOI":"10.1177\/1759720X21996973","volume":"13","author":"J Evans","year":"2021","unstructured":"Evans J, Sapsford M, McDonald S, Poole K, Raine T, Jadon DR. Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review. Ther Adv Musculoskelet Dis. 2021;13:1759720X2199697.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"779_CR17","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/rheumatology\/keab901","volume":"61","author":"D Poddubnyy","year":"2022","unstructured":"Poddubnyy D, Sieper J, Akar S, et al. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results. Rheumatology (Oxford). 2022;61:3299\u2013308.","journal-title":"Rheumatology (Oxford)"},{"key":"779_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","volume":"68","author":"C Stolwijk","year":"2016","unstructured":"Stolwijk C, van Onna M, Boonen A, van Tubergen A. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken). 2016;68:1320\u201331.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"779_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13075-016-1027-9","volume":"18","author":"R Burgos-Vargas","year":"2016","unstructured":"Burgos-Vargas R, Wei JC-C, Rahman MU, et al. The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study. Arthritis Res Ther. 2016;18:132.","journal-title":"Arthritis Res Ther"},{"key":"779_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25\u201331.","journal-title":"Ann Rheum Dis"},{"key":"779_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/ard.2004.028753","volume":"64","author":"J Sieper","year":"2005","unstructured":"Sieper J. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005;64:659\u201363.","journal-title":"Ann Rheum Dis"},{"key":"779_CR22","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1136\/ard.2004.033472","volume":"64","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X. Radiographic progression in patients with ankylosing spondylitis after 2\u00a0years of treatment with the tumour necrosis factor antibody infliximab. Ann Rheum Dis. 2005;64:1462\u20136.","journal-title":"Ann Rheum Dis"},{"key":"779_CR23","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1093\/rheumatology\/kead503","volume":"63","author":"H Santos","year":"2024","unstructured":"Santos H, Henriques AR, Machado PM, et al. Determinants of health-related quality of life and global functioning and health in axSpA, pSpA and PsA: results from the ASAS-PerSpA study. Rheumatology. 2024;63:1938\u201348.","journal-title":"Rheumatology"},{"key":"779_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5152\/eurjrheum.2021.21022","volume":"9","author":"K Narendra Reddy","year":"2022","unstructured":"Narendra Reddy K, Sabu N, Pandey N, Raut A, Joag K, Patil P. Anxiety and depression among patients with axial spondyloarthritis. Eur J Rheumatol. 2022;9:8\u201313.","journal-title":"Eur J Rheumatol"},{"key":"779_CR25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12875-020-01274-y","volume":"21","author":"KL Lapane","year":"2020","unstructured":"Lapane KL, Khan S, Shridharmurthy D, et al. Primary care physician perspectives on barriers to diagnosing axial spondyloarthritis: a qualitative study. BMC Fam Pract. 2020;21:204.","journal-title":"BMC Fam Pract"},{"key":"779_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/1756-185X.13752","volume":"23","author":"JC Wei","year":"2020","unstructured":"Wei JC, Liu C, Tseng J, et al. Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis. Int J Rheum Dis. 2020;23:7\u201323.","journal-title":"Int J Rheum Dis"},{"key":"779_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19\u201334.","journal-title":"Ann Rheum Dis"},{"key":"779_CR28","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol (Hoboken, NJ). 2019;71:1599\u2013613.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"779_CR29","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41584-023-01034-z","volume":"19","author":"W Bautista-Molano","year":"2023","unstructured":"Bautista-Molano W, Fern\u00e1ndez-\u00c1vila DG, Brance ML, et al. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis. Nat Rev Rheumatol. 2023;19:724\u201337.","journal-title":"Nat Rev Rheumatol"},{"key":"779_CR30","doi-asserted-by":"crossref","unstructured":"Alnaqbi K, Al Enizi A, Abdulkarim SNSA, et al. POS1494-HPR consensus recommendations for referral, diagnosis, monitoring, and management of axial spondyloarthritis in the Gulf region. Ann Rheum Dis. 2024;83(Suppl 1):1212\u20133.","DOI":"10.1136\/annrheumdis-2024-eular.2981"},{"key":"779_CR31","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10067-021-06019-5","volume":"41","author":"H Al Rayes","year":"2022","unstructured":"Al Rayes H, Alazmi M, Alderaan K, et al. Expert recommendations on early diagnosis and referral of axial spondyloarthritis in the Kingdom of Saudi Arabia. Clin Rheumatol. 2022;41:991\u20131002.","journal-title":"Clin Rheumatol"},{"key":"779_CR32","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2025. Available from http:\/\/www.gradepro.org."},{"key":"779_CR33","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from http:\/\/www.guidelinedevelopment.org\/handbook."},{"key":"779_CR34","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928\u2013d5928.","journal-title":"BMJ"},{"key":"779_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"779_CR36","doi-asserted-by":"publisher","DOI":"10.5867\/medwave.2021.02.8109","volume":"21","author":"M Kirmayr","year":"2021","unstructured":"Kirmayr M, Quilodr\u00e1n C, Valente B, Loezar C, Garegnani L, Franco JVA. The GRADE approach, Part 1: how to assess the certainty of the evidence. Medwave. 2021;21:e8109.","journal-title":"Medwave"},{"key":"779_CR37","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876\u201386.","journal-title":"Arthritis Rheum"},{"key":"779_CR38","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/ard.2003.016717","volume":"63","author":"J Brandt","year":"2004","unstructured":"Brandt J. Development and preselection of criteria for short term improvement after anti-TNF treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63:1438\u201344.","journal-title":"Ann Rheum Dis"},{"key":"779_CR39","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2017-212076","volume":"77","author":"U Kiltz","year":"2018","unstructured":"Kiltz U, Van Der Heijde D, Boonen A, et al. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis. 2018;77:1311\u20137.","journal-title":"Ann Rheum Dis"},{"key":"779_CR40","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","volume":"74","author":"U Kiltz","year":"2015","unstructured":"Kiltz U, van der Heijde D, Boonen A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis. 2015;74:830\u20135.","journal-title":"Ann Rheum Dis"},{"key":"779_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47\u201353.","journal-title":"Ann Rheum Dis"},{"key":"779_CR42","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/art.10883","volume":"48","author":"J Braun","year":"2003","unstructured":"Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003;48:1126\u201336.","journal-title":"Arthritis Rheum"},{"key":"779_CR43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/ard.2005.040758","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:316\u201320.","journal-title":"Ann Rheum Dis"},{"key":"779_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102234","volume":"64","author":"CA Conran","year":"2022","unstructured":"Conran CA, Moreland LW. A review of biosimilars for rheumatoid arthritis. Curr Opin Pharmacol. 2022;64:102234.","journal-title":"Curr Opin Pharmacol"},{"key":"779_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2217\/imt-2017-0001","volume":"9","author":"D Wendling","year":"2017","unstructured":"Wendling D, Prati C. Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis. Immunotherapy. 2017;9:221\u20133.","journal-title":"Immunotherapy"},{"key":"779_CR46","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2106\/00004623-196951040-00012","volume":"51","author":"WH Harris","year":"1969","unstructured":"Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969;51:737\u201355.","journal-title":"J Bone Joint Surg Am"},{"key":"779_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.62.2.127","volume":"62","author":"L Heuft-Dorenbosch","year":"2003","unstructured":"Heuft-Dorenbosch L, Spoorenberg A, Van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62:127.","journal-title":"Ann Rheum Dis"},{"key":"779_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13075-021-02695-5","volume":"24","author":"M Llop","year":"2022","unstructured":"Llop M, Moreno M, Navarro-Comp\u00e1n V, et al. Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO. Arthritis Res Ther. 2022;24:30.","journal-title":"Arthritis Res Ther"},{"key":"779_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"MCW Creemers","year":"2004","unstructured":"Creemers MCW, Franssen MJAM, Van\u2019t Hof MA, Gribnau FWJ, Van De Putte LBA, Van Riel PLCM. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2004;64:127.","journal-title":"Ann Rheum Dis"},{"key":"779_CR50","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s12325-022-02064-x","volume":"39","author":"X Juanola","year":"2022","unstructured":"Juanola X, Ramos MJM, Belzunegui JM, Fern\u00e1ndez-Carballido C, Gratac\u00f3s J. Treatment failure in axial spondyloarthritis: insights for a standardized definition. Adv Ther. 2022;39:1490\u2013501.","journal-title":"Adv Ther"},{"key":"779_CR51","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D Van Der Heijde","year":"2009","unstructured":"Van Der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811\u20138.","journal-title":"Ann Rheum Dis"},{"key":"779_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152078","volume":"56","author":"AS Pinto","year":"2022","unstructured":"Pinto AS, Farisogullari B, Machado PM. Predictors of remission in people with axial spondyloarthritis: a systematic literature review. Semin Arthritis Rheum. 2022;56:152078.","journal-title":"Semin Arthritis Rheum"},{"key":"779_CR53","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.21445","volume":"53","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum. 2005;53:703\u20139.","journal-title":"Arthritis Rheum"},{"key":"779_CR54","doi-asserted-by":"publisher","first-page":"452","DOI":"10.20452\/pamw.993","volume":"120","author":"R van den Berg","year":"2010","unstructured":"van den Berg R, van der Heijde DMFM. How should we diagnose spondyloarthritis according to the ASAS classification criteria. Pol Arch Med Wewn\u0119trznej. 2010;120:452\u20138.","journal-title":"Pol Arch Med Wewn\u0119trznej"},{"key":"779_CR55","doi-asserted-by":"publisher","first-page":"1759720X2097588","DOI":"10.1177\/1759720X20975888","volume":"12","author":"T Gudu","year":"2020","unstructured":"Gudu T, Jadon DR. Multidisciplinary working in the management of axial and peripheral spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975888.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"779_CR56","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/1759720X12458372","volume":"4","author":"IE van der Horst-Bruinsma","year":"2012","unstructured":"van der Horst-Bruinsma IE, Nurmohamed MT. Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2012;4:413\u201322.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"779_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/annrheumdis-2019-216034","volume":"79","author":"U Kiltz","year":"2020","unstructured":"Kiltz U, Landew\u00e9 RBM, van Der Heijde D, et al. Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Ann Rheum Dis. 2020;79:193\u2013201.","journal-title":"Ann Rheum Dis"},{"key":"779_CR58","doi-asserted-by":"crossref","unstructured":"Ozgocmen S. Nonpharmacologic management of axial spondyloarthritis. Axial spondyloarthritis. St Louis (MO): Elsevier; 2020. p. 203\u201316.","DOI":"10.1016\/B978-0-323-56800-5.00013-8"},{"key":"779_CR59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/bmj.38926.629329.AE","volume":"333","author":"G Elwyn","year":"2006","unstructured":"Elwyn G. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006;333:417.","journal-title":"BMJ"},{"key":"779_CR60","doi-asserted-by":"crossref","unstructured":"Mopo\u0437 \u0413\u0417, \u0413o\u043bo\u0432a\u043do\u0432a IA, \u0411\u0438\u0447\u043ao\u0432a CA, \u0414\u0437i\u0437i\u043dc\u044c\u043aa OO. Current aspects of engaging patients to shared decision-making and partner participation in the treatment process. \u041a\u043bi\u043di\u0447\u043da \u0442a \u043fpo\u0444i\u043ba\u043a\u0442\u0438\u0447\u043da \u043ce\u0434\u0438\u0446\u0438\u043da. 2023;89\u201398.","DOI":"10.31612\/2616-4868.2(24).2023.13"},{"key":"779_CR61","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","volume":"80","author":"A Molto","year":"2021","unstructured":"Molto A, L\u00f3pez-Medina C, Van Den Bosch FE, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis. 2021;80:1436\u201344.","journal-title":"Ann Rheum Dis"},{"key":"779_CR62","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/ard.2009.111187","volume":"69","author":"SJ Pedersen","year":"2010","unstructured":"Pedersen SJ, S\u00f8rensen IJ, Hermann KGA, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor \u03b1 inhibitors. Ann Rheum Dis. 2010;69:1065\u201371.","journal-title":"Ann Rheum Dis"},{"key":"779_CR63","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3899\/jrheum.110279","volume":"38","author":"PM Machado","year":"2011","unstructured":"Machado PM, Landew\u00e9 RB, van der Heijde DM. Endorsement of definitions of disease activity states and improvement scores for the ankylosing spondylitis disease activity score: results from OMERACT 10. J Rheumatol. 2011;38:1502\u20136.","journal-title":"J Rheumatol"},{"key":"779_CR64","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3899\/jrheum.2023-1217","volume":"51","author":"S Georgiadis","year":"2024","unstructured":"Georgiadis S, \u00d8rnbjerg LM, Michelsen B, et al. ASDAS-CRP and ASDAS-ESR cut-offs for disease activity states in axial spondyloarthritis\u2014are they interchangeable? J Rheumatol. 2024;51:673\u20137.","journal-title":"J Rheumatol"},{"key":"779_CR65","doi-asserted-by":"publisher","first-page":"242","DOI":"10.55563\/clinexprheumatol\/fsluso","volume":"39","author":"G Khoury","year":"2021","unstructured":"Khoury G, Combe B, Morel J, Lukas C. Change in MRI in patients with spondyloarthritis treated with anti-TNF agents: systematic review of the literature and meta-analysis. Clin Exp Rheumatol. 2021;39:242\u201352.","journal-title":"Clin Exp Rheumatol"},{"key":"779_CR66","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2\u00a0years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75:1438\u201343.","journal-title":"Ann Rheum Dis"},{"key":"779_CR67","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, van der Heijde D, Landew\u00e9 R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756\u201365.","journal-title":"Arthritis Rheum"},{"key":"779_CR68","doi-asserted-by":"crossref","unstructured":"Fan M, Liu J, Zhao B, Wu X, Li X, Gu J. Indirect comparison of NSAIDs for ankylosing spondylitis: network meta\u2011analysis of randomized, double\u2011blinded, controlled trials. Exp Ther Med. 2020;19(4):3031\u201341.","DOI":"10.3892\/etm.2020.8564"},{"key":"779_CR69","doi-asserted-by":"crossref","unstructured":"Miao X-P, Li J-S, Ouyang Q, Hu R-W, Zhang Y, Li H-Y. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. Cochrane Database Syst Rev. 2014;2014(10):CD007744.","DOI":"10.1002\/14651858.CD007744.pub2"},{"key":"779_CR70","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","volume":"4","author":"WJ Sandborn","year":"2006","unstructured":"Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled. Pilot Study Clin Gastroenterol Hepatol. 2006;4:203\u201311.","journal-title":"Pilot Study Clin Gastroenterol Hepatol"},{"key":"779_CR71","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0399-8320(04)95280-3","volume":"28","author":"L Beaugerie","year":"2004","unstructured":"Beaugerie L, Thi\u00e9fin G. Complications intestinales li\u00e9es aux AINS. Gastroenterol Clin Biol. 2004;28:62\u201372.","journal-title":"Gastroenterol Clin Biol"},{"key":"779_CR72","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1097\/00005344-200605001-00013","volume":"47","author":"CJ Hawkey","year":"2006","unstructured":"Hawkey CJ. NSAIDs, Coxibs, and the intestine. J Cardiovasc Pharmacol. 2006;47:S72\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"key":"779_CR73","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jbspin.2004.10.004","volume":"72","author":"G Thi\u00e9fin","year":"2005","unstructured":"Thi\u00e9fin G, Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Jt Bone Spine. 2005;72:286\u201394.","journal-title":"Jt Bone Spine"},{"key":"779_CR74","doi-asserted-by":"publisher","first-page":"178","DOI":"10.21037\/atm-23-195","volume":"11","author":"C Tian","year":"2023","unstructured":"Tian C, Shu J, Shao W, Zhou Z, Guo H, Wang J. Efficacy and safety of IL inhibitors, TNF-\u03b1 inhibitors, and JAK inhibitors in patients with ankylosing spondylitis: a systematic review and Bayesian network meta-analysis. Ann Transl Med. 2023;11:178\u2013178.","journal-title":"Ann Transl Med"},{"key":"779_CR75","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase\u00a0III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80:1004\u201313.","journal-title":"Ann Rheum Dis"},{"key":"779_CR76","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","volume":"81","author":"K Lauper","year":"2022","unstructured":"Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019 collaboration. Ann Rheum Dis. 2022;81:1358\u201366.","journal-title":"Ann Rheum Dis"},{"key":"779_CR77","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/rheumatology\/kead598","volume":"63","author":"A Deodhar","year":"2024","unstructured":"Deodhar A, Machado PM, M\u00f8rup M, et al. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. Rheumatology. 2024;63:1195\u2013205.","journal-title":"Rheumatology"},{"key":"779_CR78","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","volume":"79","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde D, Gensler LS, Deodhar A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase\u00a0IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79:595\u2013604.","journal-title":"Ann Rheum Dis"},{"key":"779_CR79","doi-asserted-by":"crossref","unstructured":"Navarro-Comp\u00e1n V, Rudwaleit M, Dubreuil M, et al. Improved pain, morning stiffness, and fatigue with bimekizumab in axial spondyloarthritis: results from the phase\u00a0III BE MOBILE studies. J Rheumatol. 2024;jrheum.2024\u20130223.","DOI":"10.3899\/jrheum.2024-0223"},{"key":"779_CR80","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landew\u00e9 R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase\u00a03 trial (BE COMPLETE). Lancet. 2023;401:38\u201348.","journal-title":"Lancet"},{"key":"779_CR81","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/art.42993","volume":"77","author":"A Deodhar","year":"2025","unstructured":"Deodhar A, Supronik J, Kivitz A, et al. Efficacy and safety of intravenous secukinumab in patients with active axial spondyloarthritis: results from a randomized, placebo-controlled, phase\u00a03 study. Arthritis Rheumatol (Hoboken, NJ). 2025;77:163\u201370.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"779_CR82","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilov\u00e1 E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized. Placebo-controlled phase\u00a0III study. Arthritis Rheumatol. 2021;73:110\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"779_CR83","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados M, Wei JCC, Landew\u00e9 R, et al. Efficacy and safety of ixekizumab through 52\u00a0weeks in two phase\u00a03, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79:176\u201385.","journal-title":"Ann Rheum Dis"},{"key":"779_CR84","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/ard-2023-224803","volume":"83","author":"X Baraliakos","year":"2024","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase\u00a03 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024;83:199\u2013213.","journal-title":"Ann Rheum Dis"},{"key":"779_CR85","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2022;400:369\u201379.","journal-title":"Lancet"},{"key":"779_CR86","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase\u00a02\/3 trial. Lancet. 2019;394:2108\u201317.","journal-title":"Lancet"},{"key":"779_CR87","doi-asserted-by":"publisher","first-page":"1759720X2097591","DOI":"10.1177\/1759720X20951733","volume":"12","author":"J Rademacher","year":"2020","unstructured":"Rademacher J, Poddubnyy D, Pleyer U. Uveitis in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975915.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"779_CR88","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/jcm13030912","volume":"13","author":"HY Kwon","year":"2024","unstructured":"Kwon HY, Kim YJ, Kim T-H, Ahn SJ. Comparison of incidence or recurrence of anterior uveitis in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors. J Clin Med. 2024;13:912.","journal-title":"J Clin Med"},{"key":"779_CR89","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti\u2013tumor necrosis factor \u03b1 agents. Arthritis Care Res (Hoboken). 2007;57:639\u201347.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"779_CR90","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/ard-2023-224699","volume":"83","author":"F Proft","year":"2024","unstructured":"Proft F, Torgutalp M, Muche B, et al. Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2\u00a0years in patients with radiographic axial spondyloarthritis from the randomised-controlle. Ann Rheum Dis. 2024;83:599\u2013607.","journal-title":"Ann Rheum Dis"},{"key":"779_CR91","first-page":"1","volume":"2019","author":"RSY Wong","year":"2019","unstructured":"Wong RSY. Disease-modifying effects of long-term and continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) in spondyloarthritis. Adv Pharmacol Sci. 2019;2019:1\u20136.","journal-title":"Adv Pharmacol Sci"},{"key":"779_CR92","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","volume":"74","author":"J Callhoff","year":"2015","unstructured":"Callhoff J, Sieper J, Wei\u00df A, Zink A, Listing J. Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74:1241\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"779_CR93","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13075-023-03051-5","volume":"25","author":"J Braun","year":"2023","unstructured":"Braun J, Blanco R, Marzo-Ortega H, et al. Two-year imaging outcomes from a phase\u00a03 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis. Arthritis Res Ther. 2023;25(1):80.","journal-title":"Arthritis Res Ther"},{"key":"779_CR94","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395:53\u201364.","journal-title":"Lancet"},{"key":"779_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-020-00171-2","volume":"5","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Mease P, Marzo-Ortega H, et al. Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52\u00a0weeks. BMC Rheumatol. 2021;5:1\u20139.","journal-title":"BMC Rheumatol"},{"key":"779_CR96","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/acr.24482","volume":"74","author":"JA Walsh","year":"2022","unstructured":"Walsh JA, Magrey MN, Baraliakos X, et al. Improvement of functioning and health with ixekizumab in the treatment of active nonradiographic axial spondyloarthritis in a 52-week, randomized, controlled trial. Arthritis Care Res. 2022;74:451\u201360.","journal-title":"Arthritis Care Res"},{"key":"779_CR97","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40744-020-00254-z","volume":"8","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Mease P, Rahman P, et al. ixekizumab improves patient-reported outcomes in non-radiographic axial spondyloarthritis: results from the coast-X trial. Rheumatol Ther. 2021;8:135\u201350.","journal-title":"Rheumatol Ther"},{"key":"779_CR98","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2022;400:369\u201379.","journal-title":"Lancet"},{"issue":"1","key":"779_CR99","first-page":"80","volume":"25","author":"G Biedro\u0144","year":"2025","unstructured":"Biedro\u0144 G, Wilk M, Nowakowski J, et al. Associations between comorbidities and patient-reported outcomes in axial spondyloarthritis: data from a single-center real-world cohort. Clin Rheumatol. 2025;25(1):80.","journal-title":"Clin Rheumatol"},{"key":"779_CR100","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/apt.15297","volume":"50","author":"C Ma","year":"2019","unstructured":"Ma C, Lee JK, Mitra AR, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50:5\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"779_CR101","doi-asserted-by":"publisher","first-page":"126","DOI":"10.31138\/mjr.33.1.126","volume":"33","author":"N Zioga","year":"2022","unstructured":"Zioga N, Kogias D, Lampropoulou V, Kafalis N, Papagoras C. Inflammatory bowel disease-related spondyloarthritis: the last unexplored territory of rheumatology. Mediterr J Rheumatol. 2022;33:126.","journal-title":"Mediterr J Rheumatol"},{"key":"779_CR102","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78:473\u20139.","journal-title":"Ann Rheum Dis"},{"key":"779_CR103","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/ni.1736","volume":"10","author":"W O\u2019Connor Jr","year":"2009","unstructured":"O\u2019Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T\u00a0cell-mediated intestinal inflammation. Nat Immunol. 2009;10:603\u20139.","journal-title":"Nat Immunol"},{"key":"779_CR104","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clim.2003.09.013","volume":"110","author":"A Ogawa","year":"2004","unstructured":"Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004;110:55\u201362.","journal-title":"Clin Immunol"},{"key":"779_CR105","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","volume":"11","author":"A Menter","year":"2021","unstructured":"Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG. Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb). 2021;11:385\u2013400.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"779_CR106","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693\u2013700.","journal-title":"Gut"},{"key":"779_CR107","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase\u00a02 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2016;111:1599\u2013607.","journal-title":"Am J Gastroenterol"},{"key":"779_CR108","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76:441-448.e2.","journal-title":"J Am Acad Dermatol"},{"key":"779_CR109","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/apt.14606","volume":"47","author":"OO Moninuola","year":"2018","unstructured":"Moninuola OO, Milligan W, Lochhead P, Khalili H. Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs ( <scp>NSAID<\/scp> s) and risk of Crohn\u2019s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018;47:1428\u201339.","journal-title":"Aliment Pharmacol Ther"},{"key":"779_CR110","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.curtheres.2008.06.009","volume":"69","author":"X-P Miao","year":"2008","unstructured":"Miao X-P, Ouyang Q, Li H-Y, Wen Z-H, Zhang D-K, Cui X-Y. Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: a systematic review and meta-analysis. Curr Ther Res. 2008;69:181\u201391.","journal-title":"Curr Ther Res"},{"key":"779_CR111","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-106.","journal-title":"Gut"},{"key":"779_CR112","doi-asserted-by":"publisher","first-page":"1759720X2093941","DOI":"10.1177\/1759720X20939410","volume":"12","author":"C Di Jiang","year":"2020","unstructured":"Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X20939410.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"42","key":"779_CR113","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3346\/jkms.2019.34.e278","volume":"34","author":"S Lee","year":"2019","unstructured":"Lee S, Park YJ, Lee JY. The effect of tumor necrosis factor-alpha inhibitors on uveitis in patients with ankylosing spondylitis. J Korean Med Sci. 2019;34(42):278.","journal-title":"J Korean Med Sci"},{"key":"779_CR114","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ajo.2016.07.016","volume":"170","author":"M Kim","year":"2016","unstructured":"Kim M, Won J-Y, Choi SY, Ju JH, Park Y-H. Anti-TNF\u03b1 treatment for HLA-B27-positive ankylosing spondylitis-related uveitis. Am J Ophthalmol. 2016;170:32\u201340.","journal-title":"Am J Ophthalmol"},{"key":"779_CR115","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447\u201351.","journal-title":"Arthritis Rheum"},{"key":"779_CR116","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/ard.2006.052092","volume":"65","author":"S Guignard","year":"2006","unstructured":"Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65:1631\u20134.","journal-title":"Ann Rheum Dis"},{"key":"779_CR117","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13075-021-02549-0","volume":"23","author":"D Roche","year":"2021","unstructured":"Roche D, Badard M, Boyer L, Lafforgue P, Pham T. Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials. Arthritis Res Ther. 2021;23:192.","journal-title":"Arthritis Res Ther"},{"key":"779_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.673984","volume":"12","author":"B Li","year":"2021","unstructured":"Li B, Li H, Zhang L, Zheng Y. Efficacy and safety of adalimumab in noninfectious uveitis: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:673984.","journal-title":"Front Pharmacol"},{"key":"779_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.620340","volume":"12","author":"A Xiong","year":"2021","unstructured":"Xiong A, Liu D, Chen H, et al. The efficacy and safety of infliximab in refractory noninfectious uveitis: a meta-analysis of observational studies. Front Pharmacol. 2021;12:620340.","journal-title":"Front Pharmacol"},{"key":"779_CR120","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/art.42788","volume":"76","author":"K Bechman","year":"2024","unstructured":"Bechman K, Yang Z, Adas M, et al. Incidence of uveitis in patients with axial spondylarthritis treated with biologics or targeted synthetics: a systematic review and network meta-analysis. Arthritis Rheumatol. 2024;76:704\u201314.","journal-title":"Arthritis Rheumatol"},{"key":"779_CR121","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1136\/annrheumdis-2024-eular.6139","volume":"83","author":"L Martin-Sierra","year":"2024","unstructured":"Martin-Sierra L, Sanchez-Bilbao L, Rueda-Gotor J, et al. AB0966 uveitis in axial spondyloarthritis: study of 309 patients in a single university center. Ann Rheum Dis. 2024;83:1796\u20137.","journal-title":"Ann Rheum Dis"},{"key":"779_CR122","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3899\/jrheum.180797","volume":"47","author":"A Mourad","year":"2020","unstructured":"Mourad A, Gniadecki R. Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis. J Rheumatol. 2020;47:59\u201365.","journal-title":"J Rheumatol"},{"key":"779_CR123","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/rheumatology\/keab784","volume":"61","author":"F Behrens","year":"2021","unstructured":"Behrens F, Sewerin P, De Miguel E, et al. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase\u00a03b trial. Rheumatology (Oxford). 2021;61:2856.","journal-title":"Rheumatology (Oxford)"},{"key":"779_CR124","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1136\/ard.2009.121533","volume":"69","author":"M Dougados","year":"2010","unstructured":"Dougados M, Combe B, Braun J, et al. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis. 2010;69:1430\u20135.","journal-title":"Ann Rheum Dis"},{"key":"779_CR125","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejim.2022.04.007","volume":"102","author":"S Li","year":"2022","unstructured":"Li S, Li F, Mao N, Wang J, Xie X. Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis. Eur J Intern Med. 2022;102:47\u201353.","journal-title":"Eur J Intern Med"},{"key":"779_CR126","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-021-02534-7","volume":"23","author":"MJ Nissen","year":"2021","unstructured":"Nissen MJ, M\u00f6ller B, Ciurea A, et al. Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors. Arthritis Res Ther. 2021;23:165.","journal-title":"Arthritis Res Ther"},{"key":"779_CR127","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/msc.1802","volume":"21","author":"A Jubber","year":"2023","unstructured":"Jubber A, Tahir H, Moorthy A. Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: a scoping literature review. Musculoskeletal Care. 2023;21:1195\u2013203.","journal-title":"Musculoskeletal Care"},{"key":"779_CR128","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1093\/rheumatology\/keae057","volume":"63","author":"F Cantini","year":"2024","unstructured":"Cantini F, Marchesoni A, Novelli L, et al. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials. Rheumatology. 2024;63:3146\u201354.","journal-title":"Rheumatology"},{"key":"779_CR129","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0049-0172(96)80003-5","volume":"25","author":"G Cunnane","year":"1996","unstructured":"Cunnane G, Brophy DP, Gibney RG, Fitzgerald O. Diagnosis and treatment of heel pain in chronic inflammatory arthritis using ultrasound. Semin Arthritis Rheum. 1996;25:383\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"779_CR130","first-page":"47","volume":"69","author":"LD Gadzhinova","year":"1997","unstructured":"Gadzhinova LD, Shubin SV, Mach ES, Urumova MM, Pushkova OV. Aliab\u2019eva AP [The local therapy of enthesitis and bursitis of the calcaneal area in seronegative spondylarthritis]. Ter Arkh. 1997;69:47\u20139.","journal-title":"Ter Arkh"},{"key":"779_CR131","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00296-016-3440-4","volume":"36","author":"P Srivastava","year":"2016","unstructured":"Srivastava P, Aggarwal A. Ultrasound-guided retro-calcaneal bursa corticosteroid injection for refractory Achilles tendinitis in patients with seronegative spondyloarthropathy: efficacy and follow-up study. Rheumatol Int. 2016;36:875\u201380.","journal-title":"Rheumatol Int"},{"key":"779_CR132","first-page":"642","volume":"29","author":"Z Huang","year":"2011","unstructured":"Huang Z, Cao J, Li T, Zheng B, Wang M, Zheng R. Efficacy and safety of ultrasound-guided local injections of etanercept into entheses of ankylosing spondylitis patients with refractory Achilles enthesitis. Clin Exp Rheumatol. 2011;29:642\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"779_CR133","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.clinthera.2023.08.002","volume":"45","author":"OB Tsechelidis","year":"2023","unstructured":"Tsechelidis OB, Sabido-Sauri R, Aydin SZ. Enthesitis in spondyloarthritis including psoriatic arthritis\u2014to inject or not to inject?: A narrative review. Clin Ther. 2023;45:852\u20139.","journal-title":"Clin Ther"},{"key":"779_CR134","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3904\/kjim.2023.194","volume":"38","author":"MR Seo","year":"2023","unstructured":"Seo MR, Yeo J, Park JW, et al. Korean treatment recommendations for patients with axial spondyloarthritis. Korean J Intern Med. 2023;38:620\u201340.","journal-title":"Korean J Intern Med"},{"key":"779_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.09.007","volume":"88","author":"M Pons","year":"2021","unstructured":"Pons M, Dougados M, Costedoat-Chalumeau N, et al. Pregnancy rates and outcomes in early axial spondyloarthritis: an analysis of the DESIR cohort. Jt Bone Spine. 2021;88:105075.","journal-title":"Jt Bone Spine"},{"issue":"2","key":"779_CR136","doi-asserted-by":"publisher","first-page":"2253956","DOI":"10.1080\/14767058.2023.2253956","volume":"36","author":"V D\u2019Ambrosio","year":"2023","unstructured":"D\u2019Ambrosio V, Vena F, Scopelliti A, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy and oligohydramnios: a review. J Matern Neonatal Med. 2023;36(2):2253956.","journal-title":"J Matern Neonatal Med"},{"key":"779_CR137","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.medcli.2021.01.009","volume":"156","author":"C Sans-Pola","year":"2021","unstructured":"Sans-Pola C, Guill\u00e9n E, Aguilera C. Nonsteroidal anti-inflammatory drug use during pregnancy. Med Cl\u00edn. 2021;156:568\u201372.","journal-title":"Med Cl\u00edn"},{"key":"779_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12884-022-04986-4","volume":"22","author":"K Dathe","year":"2022","unstructured":"Dathe K, Frank J, Padberg S, Hultzsch S, Beck E, Schaefer C. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German embryotox cohort. BMC Pregnancy Childbirth. 2022;22:1\u201311.","journal-title":"BMC Pregnancy Childbirth"},{"key":"779_CR139","unstructured":"R\u00fcegg L, Pluma A, Hamroun S, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 202584(6):910\u201326."},{"key":"779_CR140","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12306-023-00786-x","volume":"108","author":"G Viroli","year":"2024","unstructured":"Viroli G, Cerasoli T, Barile F, et al. Diagnosis and treatment of acute inflammatory sacroiliitis in pregnant or post-partum women: a systematic review of the current literature. Musculoskelet Surg. 2024;108:133\u20138.","journal-title":"Musculoskelet Surg"},{"key":"779_CR141","doi-asserted-by":"crossref","unstructured":"Kokar S, Kayhan \u00d6, \u015eencan S, Hakan G\u00fcnd\u00fcz O, \u00dcniversitesi Cerrahpa\u015fa-Cerrahpa\u015fa T\u0131p Fak\u00fcltesi Fiziksel T\u0131p ve Rehabilitasyon Anabilim Dal\u0131 \u0130, Y\u00f6netimi B\u00f6l\u00fcm\u00fc A. The role of sacroiliac joint steroid injections in the treatment of axial spondyloarthritis. Arch Rheumatol. 2021;36:80.","DOI":"10.46497\/ArchRheumatol.2021.8043"},{"key":"779_CR142","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","volume":"42","author":"DO Clegg","year":"1999","unstructured":"Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42:2325\u20139.","journal-title":"Arthritis Rheum"},{"key":"779_CR143","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001658","volume":"7","author":"SC Rodriguez-Garc\u00eda","year":"2021","unstructured":"Rodriguez-Garc\u00eda SC, Castellanos-Moreira R, Uson J, et al. Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews. RMD Open. 2021;7:e001658.","journal-title":"RMD Open"},{"key":"779_CR144","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1093\/rheumatology\/keab275","volume":"60","author":"V Dhir","year":"2021","unstructured":"Dhir V, Mishra D, Samanta J. Glucocorticoids in spondyloarthritis\u2014systematic review and real-world analysis. Rheumatology. 2021;60:4463\u201375.","journal-title":"Rheumatology"},{"key":"779_CR145","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard-2023-224185","volume":"82","author":"H So","year":"2023","unstructured":"So H, Lam TO, Meng H, Lam SHM, Tam L-S. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82:1387\u201393.","journal-title":"Ann Rheum Dis"},{"key":"779_CR146","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/RHU.0000000000001584","volume":"28","author":"B Nam","year":"2022","unstructured":"Nam B, Kim T-H, Lee SW, et al. Efficacy and safety of intra-articular sacroiliac glucocorticoid injections in ankylosing spondylitis. JCR J Clin Rheumatol. 2022;28:e26-32.","journal-title":"JCR J Clin Rheumatol"},{"key":"779_CR147","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13075-020-02288-8","volume":"22","author":"SR Manica","year":"2020","unstructured":"Manica SR, Sepriano A, Pimentel-Santos F, et al. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant? Arthritis Res Ther. 2020;22:195.","journal-title":"Arthritis Res Ther"},{"key":"779_CR148","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13075-016-0969-2","volume":"18","author":"A Ciurea","year":"2016","unstructured":"Ciurea A, Exer P, Weber U, et al. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther. 2016;18:71.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"779_CR149","doi-asserted-by":"publisher","first-page":"rkae141","DOI":"10.1093\/rap\/rkae141","volume":"8","author":"S Ahmed","year":"2024","unstructured":"Ahmed S, Yesudian R, Ubaide H, Coates LC. Rationale and concerns for using JAK inhibitors in axial spondyloarthritis. Rheumatol Adv Pract. 2024;8(4):rkae141.","journal-title":"Rheumatol Adv Pract"},{"key":"779_CR150","doi-asserted-by":"publisher","first-page":"129","DOI":"10.31138\/mjr.34.2.129","volume":"34","author":"K Klavdianou","year":"2023","unstructured":"Klavdianou K, Papagoras C, Baraliakos X. JAK inhibitors for the treatment of axial spondyloarthritis. Mediterr J Rheumatol. 2023;34:129.","journal-title":"Mediterr J Rheumatol"},{"key":"779_CR151","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3904\/kjim.2023.194.e1","volume":"39","author":"MR Seo","year":"2024","unstructured":"Seo MR, Yeo J, Park JW, et al. Korean treatment recommendations for patients with axial spondyloarthritis. Korean J Intern Med. 2024;39:200.","journal-title":"Korean J Intern Med"},{"key":"779_CR152","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/bcp.15806","volume":"89","author":"L Uhrenholt","year":"2023","unstructured":"Uhrenholt L, Duch K, Christensen R, et al. Predicting successful biologics tapering in patients with inflammatory arthritis: secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial. Br J Clin Pharmacol. 2023;89:3152\u201364.","journal-title":"Br J Clin Pharmacol"},{"key":"779_CR153","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","volume":"79","author":"RB Landew\u00e9","year":"2020","unstructured":"Landew\u00e9 RB, van der Heijde D, Dougados M, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis. 2020;79:920\u20138.","journal-title":"Ann Rheum Dis"},{"key":"779_CR154","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","volume":"392","author":"R Landew\u00e9","year":"2018","unstructured":"Landew\u00e9 R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 2018;392:134\u201344.","journal-title":"Lancet"},{"key":"779_CR155","doi-asserted-by":"crossref","unstructured":"Cantini F, Laura N, Cassara E, Kaloudi O, Carlotta N. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biol Targets Ther. 2013;7:1\u20136.","DOI":"10.2147\/BTT.S31474"},{"key":"779_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101869","volume":"37","author":"Z Lukasik","year":"2023","unstructured":"Lukasik Z, Carron P, Webers C. To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: that is the question. Best Pract Res Clin Rheumatol. 2023;37:101869.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"779_CR157","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10067-007-0674-2","volume":"27","author":"S-H Lee","year":"2008","unstructured":"Lee S-H, Lee Y-A, Hong S-J, Yang H-I. Etanercept 25\u00a0mg\/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol. 2008;27:179\u201381.","journal-title":"Clin Rheumatol"},{"key":"779_CR158","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","volume":"29","author":"J Lee","year":"2010","unstructured":"Lee J, Noh J-W, Hwang JW, et al. Extended dosing of etanercept 25\u00a0mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol. 2010;29:1149\u201354.","journal-title":"Clin Rheumatol"},{"key":"779_CR159","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","volume":"30","author":"V Navarro-Comp\u00e1n","year":"2011","unstructured":"Navarro-Comp\u00e1n V, Moreira V, Ariza-Ariza R, Hern\u00e1ndez-Cruz B, Vargas-Lebr\u00f3n C, Navarro-Sarabia F. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30:993\u20136.","journal-title":"Clin Rheumatol"},{"key":"779_CR160","first-page":"884","volume":"36","author":"F Lian","year":"2018","unstructured":"Lian F, Zhou J, Wang Y, Chen D, Xu H, Liang L. Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis. Clin Exp Rheumatol. 2018;36:884\u201390.","journal-title":"Clin Exp Rheumatol"},{"key":"779_CR161","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3899\/jrheum.141335","volume":"42","author":"M Yates","year":"2015","unstructured":"Yates M, Hamilton LE, Elender F, et al. Is etanercept 25\u00a0mg once weekly as effective as 50\u00a0mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial. J Rheumatol. 2015;42:1177\u201385.","journal-title":"J Rheumatol"},{"key":"779_CR162","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","volume":"55","author":"V Navarro-Comp\u00e1n","year":"2016","unstructured":"Navarro-Comp\u00e1n V, Plasencia-Rodr\u00edguez C, de Miguel E, et al. Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology. 2016;55:1188\u201394.","journal-title":"Rheumatology"},{"key":"779_CR163","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13075-020-02188-x","volume":"22","author":"D Vinson","year":"2020","unstructured":"Vinson D, Molet-Benhamou L, Degbo\u00e9 Y, et al. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. Arthritis Res Ther. 2020;22:97.","journal-title":"Arthritis Res Ther"},{"key":"779_CR164","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","volume":"80","author":"RB Landew\u00e9","year":"2021","unstructured":"Landew\u00e9 RB, Gensler LS, Poddubnyy D, et al. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Ann Rheum Dis. 2021;80:1022\u201330.","journal-title":"Ann Rheum Dis"},{"key":"779_CR165","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s10067-018-4084-4","volume":"37","author":"X Chen","year":"2018","unstructured":"Chen X, Zhang T, Wang W, Xue J. Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission. Clin Rheumatol. 2018;37:1625\u201332.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"779_CR166","first-page":"80","volume":"36","author":"S Kokar","year":"2021","unstructured":"Kokar S, Kayhan \u00d6, \u015eencan S, G\u00fcnd\u00fcz OH. The role of sacroiliac joint steroid injections in the treatment of axial spondyloarthritis. Arch Rheumatol. 2021;36(1):80.","journal-title":"Arch Rheumatol"},{"issue":"3","key":"779_CR167","doi-asserted-by":"publisher","first-page":"e1932","DOI":"10.1002\/msc.1932","volume":"22","author":"PD Vu","year":"2024","unstructured":"Vu PD, Malik A, Ryder A, Enaohwo O, Blazek G, Chen JW. The role of corticosteroid injections in the treatment of sacroiliitis: a narrative review. Musculoskeletal Care. 2024;22(3):e1932.","journal-title":"Musculoskeletal Care"},{"key":"779_CR168","unstructured":"Phillips JK, Ford MA, Bonnie RJ. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Washington (DC): National Academies Press (US); 2017."},{"key":"779_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-43321-5","volume":"13","author":"P Saisirivechakun","year":"2023","unstructured":"Saisirivechakun P, Mahakkanukrauh A, Pongchaiyakul C, et al. Prevalence of low trabecular bone score and its association with disease severity and activity in patients with axial spondyloarthritis. Sci Rep. 2023;13:1\u201310.","journal-title":"Sci Rep"},{"key":"779_CR170","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semarthrit.2017.12.001","volume":"48","author":"J Ram\u00edrez","year":"2018","unstructured":"Ram\u00edrez J, Nieto-Gonz\u00e1lez JC, Curbelo Rodr\u00edguez R, Casta\u00f1eda S, Carmona L. Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48:44\u201352.","journal-title":"Semin Arthritis Rheum"},{"key":"779_CR171","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.semarthrit.2014.05.008","volume":"44","author":"NN Haroon","year":"2014","unstructured":"Haroon NN, Sriganthan J, Al Ghanim N, Inman RD, Cheung AM. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:155\u201361.","journal-title":"Semin Arthritis Rheum"},{"key":"779_CR172","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/acr.22519","volume":"67","author":"S Siu","year":"2015","unstructured":"Siu S, Haraoui B, Bissonnette R, et al. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (Hoboken). 2015;67:754\u201364.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"779_CR173","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","volume":"77","author":"D Van Der Heijde","year":"2018","unstructured":"Van Der Heijde D, Baraliakos X, Hermann KGA, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase\u00a0III randomised trial. Ann Rheum Dis. 2018;77:699\u2013705.","journal-title":"Ann Rheum Dis"},{"key":"779_CR174","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007854","volume":"96","author":"J-H Park","year":"2017","unstructured":"Park J-H, Lee S-G, Jeon Y-K, Park E-K, Suh Y-S, Kim H-O. Relationship between serum adipokine levels and radiographic progression in patients with ankylosing spondylitis. Medicine (Baltimore). 2017;96:e7854.","journal-title":"Medicine (Baltimore)"},{"key":"779_CR175","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/annrheumdis-2021-220136","volume":"81","author":"T Diekhoff","year":"2022","unstructured":"Diekhoff T, Eshed I, Radny F, et al. Choose wisely: imaging for diagnosis of axial spondyloarthritis. Ann Rheum Dis. 2022;81:237\u201342.","journal-title":"Ann Rheum Dis"},{"key":"779_CR176","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/ard.2008.091793","volume":"68","author":"R Landewe","year":"2009","unstructured":"Landewe R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 2009;68:863\u20137.","journal-title":"Ann Rheum Dis"},{"key":"779_CR177","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/ard.2004.029728","volume":"64","author":"A Wanders","year":"2005","unstructured":"Wanders A. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis. 2005;64:988\u201394.","journal-title":"Ann Rheum Dis"},{"key":"779_CR178","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1136\/ard.2009.124206","volume":"69","author":"P Machado","year":"2010","unstructured":"Machado P, Landewe R, Braun J, Hermann K-GA, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis. 2010;69:1465\u201370.","journal-title":"Ann Rheum Dis"},{"key":"779_CR179","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13075-021-02600-0","volume":"23","author":"F Ometto","year":"2021","unstructured":"Ometto F, Ortolan A, Farber D, et al. Mediterranean diet in axial spondyloarthritis: an observational study in an Italian monocentric cohort. Arthritis Res Ther. 2021;23:219.","journal-title":"Arthritis Res Ther"},{"key":"779_CR180","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/ard.62.3.208","volume":"62","author":"L Sk\u00f6ldstam","year":"2003","unstructured":"Sk\u00f6ldstam L, Hagfors L, Johansson G. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:208\u201314.","journal-title":"Ann Rheum Dis"},{"key":"779_CR181","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.3390\/nu14224730","volume":"14","author":"P Vergne-Salle","year":"2022","unstructured":"Vergne-Salle P, Salle L, Fressinaud-Marie AC, et al. Diet and disease activity in patients with axial spondyloarthritis: spondyloarthritis and NUTrition Study (SANUT). Nutrients. 2022;14:4730.","journal-title":"Nutrients"},{"key":"779_CR182","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/03009740600844357","volume":"35","author":"B Sundstr\u00f6m","year":"2006","unstructured":"Sundstr\u00f6m B, St\u00e5lnacke K, Hagfors L, Johansson G. Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis. Scand J Rheumatol. 2006;35:359\u201362.","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"779_CR183","first-page":"247","volume":"2","author":"NP Gon\u00e7alves","year":"2023","unstructured":"Gon\u00e7alves NP, Em\u00edlia Santos M, Silv\u00e9rio-Ant\u00f3nio M, Donato H, Pimentel-Santos FM, Cruz E. The effects of physical exercise on axial spondyloarthritis\u2014a systematic review. ARP Rheumatol. 2023;2(3):247\u201364.","journal-title":"ARP Rheumatol"},{"key":"779_CR184","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/healthcare10010132","volume":"10","author":"LP Gravaldi","year":"2022","unstructured":"Gravaldi LP, Bonetti F, Lezzerini S, De Maio F. Effectiveness of physiotherapy in patients with ankylosing spondylitis: a systematic review and meta-analysis. Healthcare. 2022;10:132.","journal-title":"Healthcare"},{"key":"779_CR185","doi-asserted-by":"crossref","unstructured":"Kjeken I, B\u00f8 I, R\u00f8nningen A, et al. A three-week multidisciplinary in-patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial. J Rehabil Med. 2013;45:260\u20137.","DOI":"10.2340\/16501977-1078"},{"key":"779_CR186","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/rheumatology\/26.1.40","volume":"26","author":"SJ Bulstrode","year":"1987","unstructured":"Bulstrode SJ, Barefoot J, Harrison RA, Clarke AK. The, role of passive stretching in the treatment of ankylosing spondylitis. Rheumatology. 1987;26:40\u20132.","journal-title":"Rheumatology"},{"key":"779_CR187","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/03009742.2023.2195726","volume":"52","author":"MAT van Wissen","year":"2023","unstructured":"van Wissen MAT, Gademan MGJ, Vliet Vlieland TPM, et al. Physical therapy in patients with rheumatoid arthritis and axial spondyloarthritis: the patients\u2019 perspective. Scand J Rheumatol. 2023;52:609\u201318.","journal-title":"Scand J Rheumatol"},{"key":"779_CR188","doi-asserted-by":"crossref","unstructured":"Zhang M, Liang Z, Tian L, et al. Effects of exercise therapy in axial spondyloarthritis: a systematic review, meta-analysis, and meta-regression of randomized trials. Arch Phys Med Rehabil. 2025;106(1):113\u201323.","DOI":"10.1016\/j.apmr.2024.06.005"},{"key":"779_CR189","doi-asserted-by":"crossref","unstructured":"Regnaux J-P, Davergne T, Palazzo C, et al. Exercise programmes for ankylosing spondylitis. Cochrane Database Syst Rev. 2019;10(10):CD011321.","DOI":"10.1002\/14651858.CD011321.pub2"},{"key":"779_CR190","doi-asserted-by":"crossref","unstructured":"Romanowski MW, \u0160piritovi\u0107 M, Rutkowski R, Dudek A, Samborski W, Straburzy\u0144ska-Lupa A. Comparison of deep tissue massage and therapeutic massage for lower back pain, disease activity, and functional capacity of ankylosing spondylitis patients: a randomized clinical pilot study. Evid Based Complement Altern Med. 2017(1):9894128.","DOI":"10.1155\/2017\/9894128"},{"key":"779_CR191","first-page":"12","volume":"4","author":"R Chunco","year":"2011","unstructured":"Chunco R. The effects of massage on pain, stiffness, and fatigue levels associated with ankylosing spondylitis: a case study. Int J Ther Massage Bodywork. 2011;4:12\u20137.","journal-title":"Int J Ther Massage Bodywork"},{"key":"779_CR192","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10103-016-1874-2","volume":"31","author":"D Stasinopoulos","year":"2016","unstructured":"Stasinopoulos D, Papadopoulos K, Lamnisos D, Stergioulas A. LLLT for the management of patients with ankylosing spondylitis. Lasers Med Sci. 2016;31:459\u201369.","journal-title":"Lasers Med Sci"},{"key":"779_CR193","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/art.33465","volume":"64","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64:1388\u201398.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"779_CR194","doi-asserted-by":"publisher","first-page":"e000153","DOI":"10.1136\/rmdopen-2015-000153","volume":"1","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, Landew\u00e9 R, Van Tubergen A, et al. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD open. 2015;1(1):e000153.","journal-title":"RMD open"},{"key":"779_CR195","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/annrheumdis-2011-200180","volume":"71","author":"HY Chung","year":"2012","unstructured":"Chung HY, Machado P, Van Der Heijde D, D\u2019Agostino MA, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis. 2012;71:809\u201316.","journal-title":"Ann Rheum Dis"},{"key":"779_CR196","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/art.41408","volume":"72","author":"E Nikiphorou","year":"2020","unstructured":"Nikiphorou E, Ramiro S, Sepriano A, Ruyssen-Witrand A, Landew\u00e9 RBM, van der Heijde D. Do smoking and socioeconomic factors influence imaging outcomes in axial spondyloarthritis? Five-year data from the DESIR cohort. Arthritis Rheumatol. 2020;72:1855\u201362.","journal-title":"Arthritis Rheumatol"},{"key":"779_CR197","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/art.39666","volume":"68","author":"M Dougados","year":"2016","unstructured":"Dougados M, Demattei C, van den Berg R, et al. Rate and predisposing factors for sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis. Arthritis Rheumatol (Hoboken, NJ). 2016;68:1904\u201313.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"779_CR198","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.semarthrit.2016.11.004","volume":"46","author":"V Villaverde-Garc\u00eda","year":"2017","unstructured":"Villaverde-Garc\u00eda V, Cobo-Ib\u00e1\u00f1ez T, Candelas-Rodr\u00edguez G, et al. The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: a systematic literature review. Semin Arthritis Rheum. 2017;46:569\u201383.","journal-title":"Semin Arthritis Rheum"},{"key":"779_CR199","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40744-023-00585-7","volume":"10","author":"YM van der Kraan","year":"2023","unstructured":"van der Kraan YM, Paap D, Lennips N, et al. Patients\u2019 needs concerning patient education in axial spondyloarthritis: a qualitative study. Rheumatol Ther. 2023;10:1349.","journal-title":"Rheumatol Ther"},{"key":"779_CR200","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jopan.2011.06.002","volume":"26","author":"L Beagley","year":"2011","unstructured":"Beagley L. Educating patients: understanding barriers, learning styles, and teaching techniques. J Peri Anesthesia Nurs. 2011;26:331\u20137.","journal-title":"J Peri Anesthesia Nurs"},{"key":"779_CR201","first-page":"739","volume":"31","author":"C Rodr\u00edguez-Lozano","year":"2013","unstructured":"Rodr\u00edguez-Lozano C, Juanola X, Cruz-Mart\u00ednez J, et al. Outcome of an education and home-based exercise programme for patients with ankylosing spondylitis: a nationwide randomized study. Clin Exp Rheumatol. 2013;31:739\u201348.","journal-title":"Clin Exp Rheumatol"},{"key":"779_CR202","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13018-019-1288-5","volume":"14","author":"H-Z Guo","year":"2019","unstructured":"Guo H-Z, Yang C-X, Tang Z-P, Wang C-X. The effects of total hip arthroplasty in treating hip bony fusion in young and middle-aged patients with ankylosing spondylitis. J Orthop Surg Res. 2019;14:253.","journal-title":"J Orthop Surg Res"},{"key":"779_CR203","unstructured":"Yoo M-C, Chung D-W, Kim J-J, Lee H-K. Total hip replacement in the ankylosing spondylitis. J Korean Rheum Assoc. 1994;1(1):23\u201332."},{"key":"779_CR204","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1054\/arth.2002.32170","volume":"17","author":"AB Joshi","year":"2002","unstructured":"Joshi AB, Markovic L, Hardinge K, Murphy JCM. Total hip arthroplasty in ankylosing spondylitis: an analysis of 181\u00a0hips. J Arthroplasty. 2002;17:427\u201333.","journal-title":"J Arthroplasty"},{"key":"779_CR205","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.arth.2009.07.003","volume":"24","author":"J Li","year":"2009","unstructured":"Li J, Xu W, Xu L, Liang Z. Hip resurfacing arthroplasty for ankylosing spondylitis. J Arthroplasty. 2009;24:1285\u201391.","journal-title":"J Arthroplasty"},{"key":"779_CR206","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4055\/cios.2017.9.3.263","volume":"9","author":"S-H Lee","year":"2017","unstructured":"Lee S-H, Lee G-W, Seol Y-J, Park K-S, Yoon T-R. Comparison of outcomes of total hip arthroplasty between patients with ankylosing spondylitis and avascular necrosis of the femoral head. Clin Orthop Surg. 2017;9:263\u20139.","journal-title":"Clin Orthop Surg"},{"key":"779_CR207","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1302\/2058-5241.4.180047","volume":"4","author":"D Lin","year":"2019","unstructured":"Lin D, Charalambous A, Hanna SA. Bilateral total hip arthroplasty in ankylosing spondylitis: a systematic review. EFORT Open Rev. 2019;4:476\u201381.","journal-title":"EFORT Open Rev"},{"key":"779_CR208","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13018-019-1170-5","volume":"14","author":"Y Wang","year":"2019","unstructured":"Wang Y, Xue C, Song K, et al. Comparison of loss of correction between PSO and VCD technique in treating thoracolumbar kyphosis secondary to ankylosing spondylitis, a minimum 2\u00a0years follow-up. J Orthop Surg Res. 2019;14:137.","journal-title":"J Orthop Surg Res"},{"key":"779_CR209","first-page":"302","volume":"52","author":"S-H Liu","year":"2025","unstructured":"Liu S-H, Kay J, Liu SH, Kay J. Disparities in diagnosis: a call for equity in radiographic axial spondyloarthritis care. J Rheumatol. 2025;52:302\u20134.","journal-title":"J Rheumatol"},{"key":"779_CR210","first-page":"344","volume":"52","author":"R Ferrandiz-Espadin","year":"2025","unstructured":"Ferrandiz-Espadin R, Rabasa G, Gasman S, et al. Disparities in time to diagnosis of radiographic axial spondyloarthritis. J Rheumatol. 2025;52:344\u201351.","journal-title":"J Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00779-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00779-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00779-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T12:03:24Z","timestamp":1758369804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00779-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":210,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00779-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hanan Al Rayes, Nayef Al Ghanim, Hajer Y. Almudaiheem, Mohamed Bedaiwi, Mansour Alazmi, Eman Alqurtas, Haifa F. Alotaibi, Waleed Hafiz, Sultana Abdulaziz, Khalidah A. Alenzi, Bedor A. Al-Omari, Ibrahim Alhomood, Jameel T. Abualenain, and Ahmed H. Al-Jedai declare that they do not have any financial relationships relevant to this article to disclose and that they have no relation or involvement with any organization that holds financial or non-financial interests in the material discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All panelists who contributed to the consensus process are listed as authors on this paper. All studies were previously published, and no informed consent was necessary or obtained for inclusion in these guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}